Abstract

Cellular senescence is considered an important tumour suppression mechanism in response to damage and oncogenic stress in early lesions. However, when senescent cells are not immune-cleared and persist in the tumour microenvironment, they can drive a variety of tumour-promoting activities, including cancer initiation, progression, and metastasis. Additionally, there is compelling evidence demonstrating a direct connection between chemo(radio)therapy-induced senescence and the development of drug resistance and cancer recurrence. Therefore, detection of senescent cells in tissues holds great promise for predicting cancer occurrence earlier, assessing tumour progression, aiding patient stratification and prognosis, and informing about the efficacy of potential senotherapies. However, effective detection of senescent cells is limited by lack of biomarkers and readout strategies suitable for in vivo clinical imaging. To this end, a nanoprobe composed of biocompatible polydopamine (PDA) nanoparticle doped with FDA-approved indocyanine green (ICG) dye, namely PDA-ICG, was designed as a contrast agent for senescence detection using photoacoustic imaging (PAI). In an in vitro model of chemotherapy-induced senescence, PDA-ICG nanoprobe showed an elevated uptake in senescent cells relative to cancer cells. In addition to its improved photostability, 2.5-fold enhancement in photoacoustic signal relative to ICG was observed. Collectively, the results indicate that the PDA-ICG nanoprobe has the potential to be used as a contrast agent for senescence detection of chemotherapy-induced senescence using PAI.

Details

Title
Photoacoustic polydopamine-indocyanine green (PDA-ICG) nanoprobe for detection of senescent cells
Author
Hartono, Muhamad 1 ; Baker, Andrew G. 2 ; Else, Thomas R. 3 ; Evtushenko, Alexander S. 1 ; Bohndiek, Sarah E. 3 ; Muñoz-Espín, Daniel 4 ; Fruk, Ljiljana 1 

 University of Cambridge, Department of Chemical Engineering and Biotechnology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
 University of Cambridge, Department of Chemical Engineering and Biotechnology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Cambridge, Early Cancer Institute, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
 University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Department of Physics, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
 University of Cambridge, Early Cancer Institute, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
Pages
29506
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3133635062
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.